Hepatitis Treatment News

A Smart + Strong Site
Subscribe to:
Hepatitis E-newsletter
Join Us:

Back to home » Hepatitis Treatment News

April 23, 2014
Sovaldi/Olysio Combo Cures 94% of Those With Liver Disease
Sovaldi and Olysio cured 94 percent of people who had genotype 1 of hepatitis C and advanced liver disease in a recent trial.
April 22, 2014
Faldaprevir, Deleobuvir & PPI-668 Combo Boasts High Cure Rate
Faldaprevir and deleobuvir plus Presidio’s PPI-668 cured 92 percent of those with genotype 1a of hepatitis C virus when given with ribavirin.
AbbVie Files for FDA Approval of '3D' Hepatitis C Regimen
AbbVie submitted a new drug application to the FDA for its “3D” combination regimen of antivirals to treat adults with genotype 1 of hepatitis C.
April 21, 2014
Hep C Drugs Saddle Largest Insurer With Enormous Expense
UnitedHealth Group, the nation’s largest insurer, paid $100 million for hepatitis C medications during the first quarter of the year.
High Cure Rates for Eight-Week Sovaldi/Ledipasvir Treatment
Eight weeks of the fixed-dose combination tablet of Sovaldi and ledipasvir can cure over 90 percent of non-cirrhotic people with genotype 1 of hepatitis C.
April 18, 2014
AbbVie’s ‘3-D’ Combo Cures 92-96% of Cirrhotic Genotype 1s
In a large trial, AbbVie’s “3-D” combination therapy cured 92 percent to 96 percent of cirrhotic study participants with genotype 1 of hepatitis C.
April 17, 2014
Sovaldi/Ledipasvir Pill Cures 94-99% of Genotype 1s
Gilead Sciences’ fixed-dose combination pill of Sovaldi and ledipasvir cured 94 percent to 99 percent of those with genotype 1 of hepatitis C.
April 16, 2014
Viral Hepatitis Kills More Europeans Than HIV by Tenfold
European Union citizens die as a result of viral hepatitis at a rate about 10 times greater than deaths related to HIV.
April 15, 2014
Perfect HIV/HCV Coinfection Cure Rate for Sovaldi/Ledipasvir
A fixed-dose combo pill of Sovaldi and ledipasvir is poised to boast a 100 percent success rate in curing hepatitis C among those coinfected with HIV.
April 14, 2014
Sovaldi-Olysio-Ribavirin Cost-Effective Over Sovaldi-Ribavirin
Twelve weeks of Sovaldi, Olysio and ribavirin is more cost effective than 24 weeks of Sovaldi and ribavirin when treating interferon-intolerant people with genotype 1 of hepatitis C virus. 
AbbVie Cocktail Cures 96% of Those With Hep C Genotype 1
The AbbVie “3-D” regimen cured 96 percent of people who had genotype 1 of hepatitis C and did not have cirrhosis.
April 11, 2014
24 Weeks of Daclatasvir & Asunaprevir Cures 82-90% of 1b's
Bristol-Myers Squibb’s daclatasvir and asunaprevir cured between 82 percent and 90 percent of people with genotype 1b of hepatitis C.
April 10, 2014
WHO Issues Hep C Screening, Care and Treatment Guidelines
The World Health Organization has issued its first guidelines for the screening, care and treatment of hepatitis C virus.
Merck’s Hep C Drugs Cure 94-98% of Treatment-Naive Genotype 1s
MK-5172 and MK-8742, with or without ribavirin, cured 94 to 98 percent of treatment-naive, non-cirrhotic people with genotype 1 of hepatitis C.
Perfect Results for Sovaldi/Ledipasvir, But Only With Ribavirin
A fixed-dose pill of Sovaldi ledipasvir, plus ribavirin, boasted perfect cure rates in treating people with hepatitis C in a recent trial.
Excellent Results Across Genotypes for Sovaldi and GS-5816
Sovaldi and GS-5816 cured about 95 percent of treatment-naive people with genotypes 1 through 6 of hepatitis C who did not have cirrhosis in a recent trial. 
April 07, 2014
Federal Agencies Update Action Plan Against Viral Hepatitis
A consortium of federal agencies has announced the release of an updated blueprint for combatting viral hepatitis in the United States.
BMS Files for FDA Approval of Daclatasvir and Asunaprevir
Bristol-Myers Squibb has filed new drug applications with the U.S. Food and Drug Administration for daclatasvir and asunaprevir to treat hepatitis C.

April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
January 2008

Quick Links
Current Issue
Hep TV
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis C
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
Tell us what you think
Would you consider using medical marijuana to help ease side-effects of hepatitis C treatment?
Not sure

USA Today/Hepatitis C Awareness Survey

Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.